FRAT2 Polyklonale Antilichaam, AbBy FluorTM 680 Vervoeging

FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.

Frequently rearranged in advanced T-cell lymphomas 2 antibodyGSK-3 binding protein FRAT2; FRAT2_HUMAN.

23401

Cytoplasm

Mouse

131-230/233

FRAT2

AbBy Fluor™ 680

KLH conjugated synthetic peptide derived from human FRAT2

WB, IF (IHC-P), IF (IHC-F), IF (ICC)

Purified by Protein A.

679nm/702nm

1µg/µl

WB (1:300-5000), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

23401

Human, Rat, Dog, Cow, Sheep